Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06984562

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer: Phase I Dose Escalation Study

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
16 (estimated)
Sponsor
Fox Chase Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer. The main questions the study aims to answer are: * Can ART improve how well radiation therapy targets the most aggressive cancer cells, while protecting the healthy tissue around the tumor? * Can ART help reduce the side effects that participants may experience during treatment? Participants will: * Undergo CT scans to plan the exact location of the radiation treatment. During this process, 1-3 small markers may be placed in or near the tumor to help with the planning. * Have a tumor biopsy, which involves taking a small sample of tissue from the cancer. * Receive 5 radiation treatments every other day over a 2-week period. * Provide blood samples before, during, and after your radiation treatment.

Conditions

Interventions

TypeNameDescription
RADIATIONAdaptive Radiation TherapyAdaptive Radiation Therapy (ART) creates a personalized radiation plan for each treatment session. This means the plan can change from day to day to more precisely target the tumor while protecting the surrounding healthy tissue. By closely shaping the radiation to match the tumor's location, ART may reduce the amount of radiation reaching nearby normal tissues. This can allow for higher, more focused doses of radiation to the tumor itself, which may help improve treatment effectiveness while reducing side effects.

Timeline

Start date
2025-08-20
Primary completion
2028-08-01
Completion
2029-08-01
First posted
2025-05-22
Last updated
2025-10-29

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06984562. Inclusion in this directory is not an endorsement.